Midbrain SERT in degenerative parkinsonisms: A 123I-FP-CIT SPECT study

Movement Disorders

Volumn 25, Issue 12, 2010, Pages 1853-1859

  Roselli, Francesco ^a,b   Pisciotta, Nicola M ^a,c   Pennelli, Michele ^a   Aniello, Maria S ^a   Gigante, Angelo ^a   De Caro, Maria F ^a   Ferrannini, Ermanno ^d   Tartaglione, Bruno ^a   Niccoli Asabella, Artor ^a   Defazio, Giovanni ^a   Livrea, Paolo ^a   Rubini, Giuseppe ^a  

^a UNIVERSITY OF BARI   (Italy)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c Santa Chiara Institute   (Italy)

^d Madonnina Hospital   (Italy)

Author keywords

123I FP CIT; Dementia with Lewy bodies; Parkinsonism; Serotonin transporter; SPECT

Indexed keywords

DOPAMINE TRANSPORTER; IOFLUPANE; RADIOPHARMACEUTICAL AGENT; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC ACCURACY; DIFFUSE LEWY BODY DISEASE; DRUG UPTAKE; ESSENTIAL TREMOR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MESENCEPHALON; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SENSITIVITY AND SPECIFICITY; SEROTONINERGIC NERVE CELL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRAIN MAPPING; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MESENCEPHALON; MIDDLE AGED; MOVEMENT DISORDERS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 77956831102     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23179     Document Type: Article

References (42)

1. Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000;15:692-698.
2. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003;18:1415-1423. (Pubitemid 38035363)
3. O'Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919-925. (Pubitemid 38747333)
4. Booij J, Bergmans P, Winogrodzka A, Speelman JD, Wolters EC. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Synapse 2001;39: 101-108.
5. Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord 2001;16:1023-1032.
6. Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community?. J Neurol Neurosurg Psychiatry 2002;73:529-534.
7. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-870.
8. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006;5:75-86.
9. Seibyl J, Jennings D, Tabamo R, Marek K. Unique roles of SPET brain imaging in clinical and research studies. Lessons from Parkinson's disease research. Q J Nucl Med Mol Imaging 2005;49:215-221.
10. Neumeyer JL, Wang S, Gao Y, et al. N-omega-fluoroalkyl analogs of (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)-tropane (beta-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 1994;37:1558-1561.
11. Scheffel U, Lever JR, Abraham P, et al. N-substituted phenyltropanes as in vivo binding ligands for rapid imaging studies of the dopamine transporter. Synapse 1997;25:345-349.
12. Hesse S, Meyer PM, Strecker K, et al. Monoamine transporter availability in Parkinson's disease patients with or without depression. Eur J Nucl Med Mol Imaging 2009;36:428-435.
13. Ruhé HG, Booij J, Reitsma JB, Schene AH. Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender. Eur J Nucl Med Mol Imaging 2009;36:841-849.
14. Cavanagh J, Patterson J, Pimlott S, et al. Serotonin transporter residual availability during long-term antidepressant therapy does not differentiate responder and nonresponder unipolar patients. Biol Psychiatry 2006;59:301-308. (Pubitemid 43238354)
15. Kim SE, Choi JY, Choe YS, Choi Y, Lee WY. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT. J Nucl Med 2003;44:870-876.
16. Murai T, Müller U, Werheid K, et al. In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001;13:222-228.
17. McKeith IG, Dickson DW, Lowe J, et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
18. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson- Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
19. Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord 1998;13:2-23.
20. Fahn S, Elton R. Members of the UPDRS development committee Unified Parkinson's rating scale. In: Fahn S, Marsden C, Calne D, Goldstein M, editors. Recent developments in Parkinson's disease, vol 2: Florhan Park: MacMillan Healthcare Information; 1987. p 153-163.
21. Folstein Mf, Folstein Se, Mchugh Pr. "Mini-Mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
22. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44: 2308-2314.
23. Tatsch K, Asenbaum S, Bartenstein P, et al. European Association of Nuclear Medicine. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands. Eur J Nucl Med Mol Imaging 2002;29:BP303-BP305.
24. Soret M, Koulibaly PM, Darcourt J, Buvat I. Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification. Eur J Nucl Med Mol Imaging 2006;33:1062-1072. (Pubitemid 44215672)
25. Zitterl W, Aigner M, Stompe T, et al. [123I]-beta-CIT SPECT imaging shows reduced thalamus-hypothalamus serotonin transporter availability in 24 drug-free obsessive-compulsive checkers. Neuropsychopharmacology 2007;32:1661-1668.
26. Van Dyck CH, Malison RT, Staley JK, et al. Central serotonin transporter availability measured with [123I]beta-CIT SPECT in relation to serotonin transporter genotype. Am J Psychiatry 2004;161:525-531.
27. Kugaya A, Sanacora G, Staley JK, et al. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry 2004;56:497-502.
28. de Win MM, Habraken JB, Reneman L, van Den Brink W, den Heeten GJ, Booij J. Validation of [(123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology 2005; 30:996-1005.
29. Brooks DJ. Technology insight: imaging neurodegeneration in Parkinson's disease. Nat Clin Pract Neurol 2008;4:267-277.
30. Booij J, de Jong J, de Bruin K, Knol R, de Win MM, van Eck- Smit BL. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med 2007; 48:359-66.
31. Caretti V, Stoffers D, Winogrodzka A, et al. Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study. J Neural Transm 2008;115:721-729.
32. Seppi K, Scherfler C, Donnemiller E, et al. Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis. Arch Neurol 2006; 63:1154-1160.
33. Kish SJ, Tong J, Hornykiewicz O, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008;131:120-131.
34. Guttman M, Boileau I, Warsh J, et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol 2007;14:523-538.
35. Haapaniemi TH, Ahonen A, Torniainen P, Sotaniemi KA, Myllylä VV. [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov Disord 2001;16:124-130. (Pubitemid 36041126)
36. Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res 1990;510:104-107. (Pubitemid 20060808)
37. Benarroch EE, Schmeichel AM, Sandroni P, Parisi JE, Low PA. Rostral raphe involvement in Lewy body dementia and multiple system atrophy. Acta Neuropathol 2007;114:213-220. (Pubitemid 47226147)
38. Jacobs BL, Wilkinson LO, Fornal CA. The role of brain serotonin. A neurophysiologic perspective. Neuropsychopharmacology 1990;3:473-479.
39. Boeve BF, Silber MH, Saper CB, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007;130:2770-2788.
40. Slowinski J, Imamura A, Uitti RJ, et al. MR imaging of brainstem atrophy in progressive supranuclear palsy. J Neurol 2008; 255:37-44.
41. Quattrone A, Nicoletti G, Messina D, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008;246:214-221.
42. Nicoletti G, Lodi R, Condino F, et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006;129:2679-2687.